Publication

Chemotherapy-free phase 1/2 trial of HRS-4642 plus adebrelimab in previously treated metastatic KRAS G12D-mutant pancreatic cancer.

Si Shi, Miaoyan Wei, Nan Du, Jialin Li, Boyue Han, Wei Wang, Xin Hu, Fei Luo, Jin Xu, Xianjun Yu

Cancer cellSep 16, 2026PMID 42748921doi:10.1016/j.ccell.2026.08.012 Journal ArticlepubmedPublished

Abstract

Abstract (excerpt)

Only the opening of the abstract is shown; abstract text may carry publisher copyright.

KRAS G12D mutations drive approximately 40% of pancreatic ductal adenocarcinoma (PDAC) cases and foster an immunosuppressive tumor microenvironment. This phase 1/2 trial (NCT06427239) evaluated HRS-4642, a selective KRAS G12D inhibitor, combined with the PD-L1 blockade adebrelimab in 48 pretreated…

Read on PubMed

Linked entities

Linked entities (2)

How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.

Validated 1

trialNCT06427239registry_reference1.00

Candidate 1

cancerMalignant Pancreatic Neoplasmdictionary0.60

Registered trialsNCT06427239

Curated evidence

Evidence citing this paper (1)

civicCuratedShowing 1–1 of 1 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
KRAS G12D1
Adebrelimab + KRAS G12D Inhibitor HRS-4642Combination	Pancreatic Ductal Adenocarcinoma	Predictive	B	Supports Sensitivity Response	3	submitted	EID13294 In this phase 1/2 trial the KRAS G12D degrader HRS-4642 in combination with PD-L1 inhibitor adebrelimab was tested in 48 pretreated KRAS G12D-positive pancreatic adenocarcinoma patients. Patients had … (full text at CIViC) PMID 42748921 · Shi et al., 2026 · Open in CIViC	civic